La cadena de opciones muestra datos clave de las opciones de acciones de PainReform a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para PainReform..

PainReform (NASDAQ:PRFX) Bolsa, Cadena de Opciones

PainReform

PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.

PainReform Ltd

Alliance Global Partners analyst Jeff Grampp upgrades Vitesse Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) from Neutral to Buy and raises the price target from $26 to $29.

News

Upgrades

Price Target

Analyst Ratings

Alliance Global Partners Upgrades Vitesse Energy to Buy, Raises Price Target to $29

WIIM

NCPL

Netcapital shares are trading lower after the company reported worse-than-expected Q2 financial results.

Wearable Devices Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>) disclosed that it will showcase the first augmented reality glasses fully controlled <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42527722/wearable-devices-and-rayneo-unveil-first-neural-controlled-ar-glasses-at-ces-2025-serving-as-the-c" rel="noreferrer noopener">by its neural wristband at CES 2025</a>.
In collaboration with RayNeo, Wearable Devices will demonstrate the intuitive gesture control experience of the Mudra Link Neural Wristband paired with RayNeo&#8217;s latest AR glasses.
This partnership highlights Wearable Devices&#8217; mission to transform human-computer interaction with seamless, hands-free control in AR environments.
Combining RayNeo&#8217;s AR expertise with Wearable Devices&#8217; neural gesture technology, this demo sets a new standard for interactivity in extended reality.
This integration cements Wearable Devices&#8217; position in neural wrist-worn solutions for the fast-growing AR and XR markets, enhancing accessibility and usability in extended reality experiences.
Asher Dahan, Chief Executive Officer of Wearable Devices said, &#8220;Our collaboration with RayNeo brings us a step closer to mass adoption of smart glasses operated by a neural wristband, highlights the transformative potential of combining Mudra Link with AR glasses, demonstrating how neural gesture control can redefine augmented reality applications across industries.&#8221;
Howie Li, Chief Executive Officer of RayNeo added, &#8220;The integration of neural gesture control with our latest AR glasses opens new possibilities for intuitive and immersive user experiences.&#8221;
Price Action: WLDS shares are down 1.89% at $1.56 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42532242" target="_blank" rel="noreferrer noopener">Salesforce Supercharges Adecco &amp; Vivint With AI: Details</a></li>
</ul>

Equities

Small Cap

WLDS

Wearable Devices To Debut Neural-Controlled Augmented Reality Glasses At CES 2025

Alliance Global Partners analyst Aaron Grey initiates coverage on Advanced Flower Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) with a Buy rating and announces Price Target of $13.

Initiation

AFCG

Alliance Global Partners Initiates Coverage On Advanced Flower Capital with Buy Rating, Announces Price Target of $13

Roth MKM analyst Darren Aftahi maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and raises the price target from $15 to $29.

BTDR

Roth MKM Maintains Buy on Bitdeer Technologies, Raises Price Target to $29

Movers

Trading Ideas

MNTS

Momentus Shares Halted For Volatility

Offerings

Momentus Announces Pricing Of Reasonable Best Efforts Offering With An Institutional Investor For Purchase And Sale Of 800K Shares Of Common Stock And Warrants At Combined Offering Price Of $6.20/Share For Gross Proceeds ~$5M

As a rule, I pay almost no attention to Wall Street analysts. I do not give much of a whoop about their opinion of a stock. Most of my biggest winners have been underfollowed or not followed by mainstream Wall Street firms. Much of the research produced for individual investors by the big Wall Street firms is more marketing than research. There are a few boutique analysts that specialize in things like banking and real estate that I read regularly, but it&#8217;s more to look for inside baseball information I may have missed and take advantage of their access to the C-suite.
What I do pay attention to are earnings surprises and revisions. When analysts revise earnings estimates upward, it&#8217;s like waving a green flag to investors. Positive revisions often signal that a company&#8217;s fundamentals are improving and that management is executing well. This can set the stage for strong stock performance, especially for patient, value-focused investors who know how to spot opportunities early.
Market sentiment plays a big role here. A positive revision often sparks optimism, driving buying activity. This momentum can push the stock price higher as more investors jump on board. Institutions, in particular, pay close attention to these revisions, and their large-scale buying can amplify the effect.
Valuation is another key factor. Higher earnings expectations make stocks look cheaper on a price-to-earnings basis, even if the price hasn&#8217;t moved yet. That&#8217;s an open invitation for investors to re-rate the stock higher. Over time, consistent upward revisions can create a narrative of reliability and growth, attracting long-term capital and putting a solid floor under the stock price.
Smart investors know to dig deeper when they see positive revisions. Look for companies with strong balance sheets, good management, and a history of exceeding expectations. Those are the ones that can turn a simple revision into substantial long-term gains. As always, patience and discipline win the race.
I am even a bigger fan of earnings surprises that happen with almost no one watching. When a company with little analyst coverage delivers a positive earnings surprise, it&#8217;s like a hidden gem finally getting noticed. These stocks often fly under the radar, and that lack of attention creates inefficiency. The market scrambles to catch up when good news hits, and the stock can take off like a rocket.
With fewer eyes on the company, there&#8217;s less information baked into the price. A strong earnings beat forces investors to reassess quickly, and the resulting buying frenzy can send shares soaring. For smaller or mid-cap names, this can also attract institutional investors who previously ignored the stock, fueling the fire.
When I sat down this week to run the list of underfollowed companies that have the key combination of positive surprise and upward revisions from the few analysts paying attention, a few names caught my eye as under-the-radar candidates for outsized gains.
Gambling.com Group Limited (Ticker: GAMB) is a powerhouse in performance marketing, laser-focused on the online gambling industry. With a portfolio of top-tier websites like &#8220;Gambling.com&#8221; and &#8220;Bookies.com,&#8221; the company connects players with online casinos and sportsbooks, driving customer acquisition for operators in regulated markets.
The company has posted three consecutive positive earnings surprises, and the few analysts who follow it have been rushing to raise estimates. Institutions are starting to notice, and the stock has been gaining momentum in the last few weeks.
LiveRamp Holdings (Ticker: RAMP) operates at the crossroads of data and marketing, carving out a niche in the rapidly growing world of data connectivity and identity resolution. Based in San Francisco, the company is essentially a high-tech bridge builder, helping businesses turn disconnected data into actionable insights while staying firmly committed to privacy and security.
LiveRamp is essentially a toll booth operator in the data economy. The more businesses lean on data to drive marketing, sales, and operations, the more valuable LiveRamp becomes.
The tailwinds here are strong. The shift to a privacy-first internet plays right into LiveRamp&#8217;s hands, and as more businesses look for ways to unlock value from their data without running afoul of regulators, demand for its solutions should continue to grow.
Only a handful of analysts are paying attention, and even they are underestimating the potential growth. LiveRamp has exceeded analyst expectations for four quarters in a row, and analysts have recently raised their estimates for this year and next. Institutions are starting to notice, and their buying has given the stock some upward momentum in the last few months.
Another company that caught my eye was about as far off Wall Street&#8217;s radar as possible. Only three analysts follow Eurosea Ltd. (Ticker: ESEA), and the last time one wrote a comment was in June. However, they have raised their estimates for both this year and next after Eurosea posted back-to-back positive earnings surprises.
Euroseas Ltd. is a niche operator in the global container shipping market. It focuses on the smaller, regional routes that the big players can&#8217;t or won&#8217;t serve. Based in Greece, Euroseas has carved out a solid position by specializing in feeder and intermediate container vessels.
Euroseas isn&#8217;t flashy, but it&#8217;s effective. It&#8217;s a pure play on the regional and feeder markets in container shipping, areas that are often overlooked but critically important to the global trade ecosystem. With its flexible business model and experienced management, it&#8217;s the kind of company that knows how to ride the waves of a cyclical industry and come out ahead.
At the current price, the stock is trading well below the value of its ships and yields more than 6%. If the company continues to exceed expectations and the institutions begin accumulating the stock, Euroseas could have substantial upside.

Opinion

ESEA

GAMB

RAMP

Under the Radar: Exploring Untapped Potential in Overlooked Stocks

Alliance Global Partners analyst Aaron Grey initiates coverage on Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) with a Buy rating and announces Price Target of $130.

IIPR

Alliance Global Partners Initiates Coverage On Innovative Ind Props with Buy Rating, Announces Price Target of $130

Roth MKM analyst Scott Fortune reiterates Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Buy and raises the price target from $55 to $70.

Reiteration

Roth MKM Reiterates Buy on Turning Point Brands, Raises Price Target to $70

Alliance Global Partners analyst Aaron Grey initiates coverage on Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) with a Buy rating and announces Price Target of $20.

REFI

Alliance Global Partners Initiates Coverage On Chicago Atlantic Real with Buy Rating, Announces Price Target of $20

Whales with a lot of money to spend have taken a noticeably bullish stance on Vertiv Hldgs.
Looking at options history for Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 35% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $83,130 and 11, calls, for a total amount of $380,240.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $65.0 to $150.0 for Vertiv Hldgs over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Vertiv Hldgs options trades today is 236.62 with a total volume of 482.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Vertiv Hldgs's big money trades within a strike price range of $65.0 to $150.0 over the last 30 days.
<h3>Vertiv Hldgs Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734452137_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$21.9</td>
<td>$21.5</td>
<td>$21.7</td>
<td>$105.00</td>
<td>$52.0K</td>
<td align="right">212</td>
<td align="right">93</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$140.00</td>
<td>$50.1K</td>
<td align="right">85</td>
<td align="right">88</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$22.8</td>
<td>$22.3</td>
<td>$22.38</td>
<td>$105.00</td>
<td>$49.1K</td>
<td align="right">212</td>
<td align="right">44</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$14.9</td>
<td>$14.6</td>
<td>$14.9</td>
<td>$115.00</td>
<td>$44.7K</td>
<td align="right">6</td>
<td align="right">37</td>
</tr>
<tr>
<td>VRT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$28.5</td>
<td>$28.0</td>
<td>$28.0</td>
<td>$145.00</td>
<td>$28.0K</td>
<td align="right">135</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About Vertiv Hldgs</h3>
Vertiv Holdings Co brings together hardware, software, analytics and ongoing services to ensure its customers vital applications run continuously, perform optimally and grow with their business needs. The company solves the important challenges faced by data centers, communication networks and commercial and industrial facilities with a portfolio of power, cooling and IT infrastructure solutions and services that extends from the cloud to the edge of the network. Its services include critical power, thermal management, racks and enclosures, monitoring and management, and other services. Its three business segments include the Americas, Asia Pacific; and Europe, Middle East &amp; Africa.
After a thorough review of the options trading surrounding Vertiv Hldgs, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Vertiv Hldgs</h3>
<ul>
<li>Trading volume stands at 2,326,990, with VRT's price down by -3.21%, positioned at $121.93.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 64 days.</li>
</ul>
<h3>What Analysts Are Saying About Vertiv Hldgs</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $137.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Vertiv Hldgs, targeting a price of $145. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Vertiv Hldgs, targeting a price of $141. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Vertiv Hldgs, which currently sits at a price target of $132. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Vertiv Hldgs, targeting a price of $131. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Vertiv Hldgs, targeting a price of $140. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertiv Hldgs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Vertiv Hldgs Unusual Options Activity For December 17

Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 63% bullish and 36%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $464,895, and 8 are calls, for a total amount of $2,906,247.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $75.0 to $130.0 for Novo Nordisk during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale activity within a strike price range from $75.0 to $130.0 in the last 30 days. 
<h3>Novo Nordisk Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734452132_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.88</td>
<td>$2.54</td>
<td>$2.82</td>
<td>$112.00</td>
<td>$1.9M</td>
<td>3.0K</td>
<td>457</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.35</td>
<td>$6.15</td>
<td>$6.21</td>
<td>$105.00</td>
<td>$386.4K</td>
<td>3.9K</td>
<td>811</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.75</td>
<td>$2.6</td>
<td>$2.61</td>
<td>$105.00</td>
<td>$261.0K</td>
<td>14.3K</td>
<td>1.9K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.1</td>
<td>$5.05</td>
<td>$5.1</td>
<td>$130.00</td>
<td>$208.5K</td>
<td>405</td>
<td>0</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.3</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$95.00</td>
<td>$176.4K</td>
<td>1.7K</td>
<td>360</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Novo Nordisk</h3>
<ul>
<li>Trading volume stands at 1,381,254, with NVO's price up by 0.24%, positioned at $108.31.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 43 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Novo Nordisk's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bullish approach towards Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMAT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Applied Mat. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 33% bearish. Among these notable options, 4 are puts, totaling $156,973, and 11 are calls, amounting to $441,260.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $195.0 for Applied Mat over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Applied Mat's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Applied Mat's whale activity within a strike price range from $140.0 to $195.0 in the last 30 days. 
<h3>Applied Mat Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734452127_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$41.9</td>
<td>$40.35</td>
<td>$41.15</td>
<td>$150.00</td>
<td>$102.8K</td>
<td>267</td>
<td align="right">25</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$15.2</td>
<td>$15.2</td>
<td>$15.2</td>
<td>$165.00</td>
<td>$54.7K</td>
<td>1.6K</td>
<td align="right">36</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$30.4</td>
<td>$30.25</td>
<td>$30.25</td>
<td>$140.00</td>
<td>$39.3K</td>
<td>900</td>
<td align="right">87</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$30.8</td>
<td>$30.2</td>
<td>$30.8</td>
<td>$140.00</td>
<td>$36.9K</td>
<td>900</td>
<td align="right">60</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.7</td>
<td>$17.5</td>
<td>$17.5</td>
<td>$170.00</td>
<td>$36.7K</td>
<td>816</td>
<td align="right">22</td>
</tr>
</tbody>
</table>

<h3>About Applied Mat</h3>
Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
Having examined the options trading patterns of Applied Mat, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Applied Mat</h3>
<ul>
<li>With a trading volume of 1,438,984, the price of AMAT is down by -0.05%, reaching $169.32.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 58 days from now.</li>
</ul>
<h3>What The Experts Say On Applied Mat</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $194.66666666666666.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Underweight with a new price target of $164. 
&#x2A; Consistent in their evaluation, an analyst from Bernstein keeps a Outperform rating on Applied Mat with a target price of $210. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Applied Mat, targeting a price of $210. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Applied Mat options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

AMAT

A Closer Look at Applied Mat's Options Market Dynamics

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 3.84% on an annualized basis producing an average annual return of 15.1%. Currently, HCA Healthcare has a market capitalization of $79.90 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $408.35 today based on a price of $309.60 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734452108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Roth MKM analyst Jason Wittes maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Buy and raises the price target from $100 to $115.

GMED

Roth MKM Maintains Buy on Globus Medical, Raises Price Target to $115

Argus Research analyst John Staszak upgrades VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) from Hold to Buy and announces $25 price target.

Argus Research Upgrades VF to Buy, Announces $25 Price Target

Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) shares are trading higher on Tuesday following the announcement <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42530864/sidus-space-announces-14-million-private-placement" rel="noreferrer noopener">of a securities offering</a>.
Sidus has entered into definitive agreements with accredited and institutional investors for the issuance and sale of units in a brokered private placement.
Each unit consists of shares of Class A common stock (or pre-funded warrants in lieu thereof) paired with common warrants to purchase additional shares of Class A common stock.
The offering is set at $2.07 per unit, with a total of approximately 6.8 million shares of Class A common stock (or pre-funded warrants) being issued.
Additionally, common warrants for 3.4 million shares will be sold, each entitling holders to purchase Class A common stock at an exercise price of $2.25 per share. The pre-funded warrants will allow the holder to acquire shares at an exercise price of $0.0001 each.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42531373/financial-stocks-near-record-year-could-trump-deregulation-fuel-bigger-gains-in-2025" rel="noreferrer noopener">Financial Stocks Near Record Year: Could Trump Deregulation Fuel Bigger Gains In 2025?</a>
The offering is expected to raise gross proceeds of around $14 million before fees and expenses. The funds will be used for general working capital and corporate purposes.
The private placement is slated to close on December 18, pending customary closing conditions.
Last month, Sidus Space successfully completed the launch processing of LizzieSat-2 at Vandenberg <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42188959/sidus-space-announces-lizziesat-2-ready-for-launch" rel="noreferrer noopener">Space Force Base in California.</a>
The satellite has been handed over to SpaceX and is ready for the Bandwagon-2 rideshare mission, set for launch in December 2024.
Price Action: SIDU shares are trading higher by 14.6% to $5.25 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42468190/defense-stocks-face-headwinds-as-trumps-doge-targets-spending-cuts-goldman-sachs-downgrades-general-dynamics-to-sell" target="_blank" rel="noreferrer noopener">Defense Stocks Face Headwinds As Trump's DOGE Targets Spending Cuts: Goldman Sachs Downgrades General Dynamics</a></li>
</ul>

General

SIDU

Why Is Sidus Space Stock Gaining Tuesday?

Oppenheimer analyst Francois Brisebois reiterates Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) with a Outperform and maintains $20 price target.

MNMD

Oppenheimer Reiterates Outperform on Mind Medicine, Maintains $20 Price Target

Argus Research analyst John Staszak upgrades Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) from Hold to Buy and announces $90 price target.

Argus Research Upgrades Boyd Gaming to Buy, Announces $90 Price Target

PainReform (PRFX) announced that it has received a notification from Nasdaq advising the company that it no longer satisfied the minimum $2.5M stoc...

PainReform receives noncompliance notification from Nasdaq

PainReform (PRFX) has released an update. PainReform Ltd. will implement a 1-for-4 reverse share split of its ordinary shares, effective after mark...

PainReform Announces 1-for-4 Reverse Share Split

PainReform (PRFX) announced the receipt of partial topline data from its contract research organization, CRO, Lotus Clinical Research, for the Phas...

PainReform announces data for PRF-110 Phase 3 trial, notes incoherence of data

PainReform drops on late-stage trial data for post-surgical pain management after bunionectomy

PainReform (PRFX) has released an update. PainReform Ltd. reported promising initial results from its Phase 3 trial of PRF-110, highlighting its po...

PainReform's PRF-110 Shows Promise in Initial Trial Results

19:50 EST PainReform (PRFX) Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

PainReform Ltd trading halted, news pending

Volato Group, PainReform Ltd., and Interactive Strength Inc. are the 3&nbsp;Penny Stocks&nbsp;to watch on November 21, 2024, based on&nbsp;TipRanks...

3 Penny Stocks to Watch Now, 11/21/24

Maxim Group analyst Naz Rahman maintained a Hold rating on PainReform (PRFX – Research Report) yesterday. The company's shares opened today at $3.3...

PainReform (PRFX) Receives a Hold from Maxim Group

PainReform (PRFX) has released an update. PainReform Ltd. has appointed Eyal Broder as the Interim Chief Financial Officer, succeeding Dr. Ehud Gel...

PainReform Ltd. Navigates Leadership Changes and Nasdaq Compliance

Which subsectors to own and which to avoid – Wolfe Research

AAPL

AMZN

BILI

BRCC

CRDO

DBAW

DFAX

ESPO

FTXG

GLBE

GOOGL

IBUY

KBWB

MAGS

MATV

MSFT

NLSP

NVDA

ONLN

PRFX

QUAL

REPYY

RGTI

SCHG

SDVY

SMOT

SOAR

SOCL

SOXX

SPYG

SPYV

SUPV

TRAW

TRNR

TROX

TSLA

TZOO

WEST

Press Releases

PainReform Announces Development and Successful Manufacturing of New Formulations Providing Anti-Inflammatory and Extended Analgesic Effects

Earnings

PainReform Provides Business Update for the Second Quarter of 2024

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Health Care

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

"Stocks Under $1 to Watch: SOAR, PRFX, NCNC, BTTC, RJDG—Breakthroughs, Surges, Market Movers!"

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

"Power Nickel (TSX.V: PNPN) (OTCQB: PNPNF) Announces Dividend – MIGI, PRFX, PBM, CSDX Stocks Trending Now!"

Comments

PainReform

PainReform (PRFX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL